Healthcare

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical…

2 months ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical…

2 months ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical…

2 months ago

Stemtech Corporation – Stemtech Healthsciences India Pvt Ltd Announces Strategy for Market Entry

NAPLES, FL / ACCESS Newswire / October 27, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell…

2 months ago

Stemtech Corporation – Stemtech Healthsciences India Pvt Ltd Announces Strategy for Market Entry

NAPLES, FL / ACCESS Newswire / October 27, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell…

2 months ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical…

2 months ago

Stemtech Corporation – Stemtech Healthsciences India Pvt Ltd Announces Strategy for Market Entry

NAPLES, FL / ACCESS Newswire / October 27, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell…

2 months ago

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of…

2 months ago

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of…

2 months ago

Trinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion – Strengthening Balance Sheet and Supporting Growth

DUBLIN, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics…

2 months ago